Xevinapant
- Generic Name
- Xevinapant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H43N5O4
- CAS Number
- 1071992-99-8
- Unique Ingredient Identifier
- N65WC8PXDD
- Associated Conditions
- -
- Associated Therapies
- -
Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG)
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 12
- Registration Number
- NCT06463184
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 42
- Registration Number
- NCT06110195
- Locations
- 🇺🇸
University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Phase 2
Withdrawn
- Conditions
- Oropharyngeal Squamous Cell CarcinomaStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Chest RadiographyDrug: CisplatinProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDrug: Xevinapant
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Registration Number
- NCT06084845
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 18
- Registration Number
- NCT06056310
- Locations
- 🇺🇸
Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Montefiore Medical Center PRIME, Bronx, New York, United States
🇧🇪Universitair Ziekenhuis Gent - Medical Oncology, Gent, Belgium
Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
Phase 3
Suspended
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
- Target Recruit Count
- 19
- Registration Number
- NCT05930938
- Locations
- 🇫🇷
Hôpital Nord Franche Compté, Montbéliard, France
Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-08-27
- Target Recruit Count
- 230
- Registration Number
- NCT05724602
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇸🇮The Institute Of Oncology, Ljubljana, Slovenia
🇳🇴Helse Bergen HF -Haukeland Hospital - Univ. Hosp, Bergen, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath